Biosimilar Interchangeability Stymied Mainly By Extrapolation Uncertainties, Amgen Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Amgen’s R&D head Miletich tells the BIO International Convention that understanding, not detecting, minor structural differences between products is a key hurdle to creating interchangeable biologics. Also, designing trials which satisfy the statute’s “any given patient” requirement is daunting.
You may also be interested in...
Biosimilar Interchangeability: Stakeholders Want More FDA Guidance, Fewer Hurdles
The limited discussion of interchangeability in FDA’s initial biosimilar draft guidances has left some stakeholders clamoring for more details. Others say the agency’s demand for a “higher standard” of evidence to show interchangeability is misplaced and will inhibit use of the 351(k) pathway.
Amgen, Watson Aim To Launch First Joint Oncology Biosimilar In U.S. In 2017
The partners’ flexibility allows them, together and separately, to establish solid footholds in a still-evolving field with plenty of potential but also uncertainties.
Pink Sheet Podcast: Relyvrio And Public Promises, Allergy Biomarker Adcomms, PMDA In The USA
Pink Sheet reporters and editor discuss the implications of Amylyx following through on its pledge to remove Relyvrio from the market after its trial failed, an FDA idea to bring potential biomarkers for promising allergy and asthma treatments to advisory committees, and Japan’s PMDA opening an office in Washington D.C.